A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Summary

This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.

Timeline

Start

2024-11-04

Primary completion

2026-04-30

Completion

2026-06-30

Drugs

Indications